StockNews.AI
ACRS
StockNews.AI
50 days

Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes

1. ACRS added to Russell 3000 and Russell 2000 Indexes today. 2. Membership enhances visibility to institutional investors and funds. 3. Russell Indexes include $10.6 trillion in benchmarked assets. 4. ACRS develops treatments for immuno-inflammatory diseases. 5. Inclusion may attract more investment interest in ACRS.

4m saved
Insight
Article

FAQ

Why Bullish?

Inclusion in major indices typically improves stock liquidity and visibility. Historical examples show similar stocks experienced positive price movements after such additions.

How important is it?

Being added to Russell indexes indicates growing recognition and potential for future investment, impacting overall market perception.

Why Short Term?

The market often reacts quickly to index inclusion news, enhancing demand. Similar events have shown price increases within weeks.

Related Companies

SPYIWMVOO
June 30, 2025 09:31 ET  | Source: Aclaris Therapeutics, Inc. WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of the conclusion of the 2025 Russell US Indexes annual reconstitution, effective at the open of US equity markets today, Monday, June 30, 2025. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Wednesday, April 30th, ranking them by total market capitalization. Membership in the US all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. For more information on the Russell 3000® Index, the Russell 2000® index, and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website. About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn. Aclaris Therapeutics Contact: Will RobertsSenior Vice PresidentCorporate Communications and Investor Relations(484) 329-2125wroberts@aclaristx.com

Related News